1. Home
  2. UAMY vs PMN Comparison

UAMY vs PMN Comparison

Compare UAMY & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United States Antimony Corporation

UAMY

United States Antimony Corporation

BUY

Current Price

$3.95

Market Cap

955.8M

Sector

Industrials

ML Signal

BUY

Logo ProMIS Neurosciences Inc. (ON)

PMN

ProMIS Neurosciences Inc. (ON)

HOLD

Current Price

$9.37

Market Cap

84.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UAMY
PMN
Founded
1968
2004
Country
United States
Canada
Employees
N/A
N/A
Industry
Metal Fabrications
Pharmaceuticals and Biotechnology
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
955.8M
84.1M
IPO Year
1997
2022

Fundamental Metrics

Financial Performance
Metric
UAMY
PMN
Price
$3.95
$9.37
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
8
Target Price
$10.44
★ $42.71
AVG Volume (30 Days)
★ 4.2M
38.0K
Earning Date
11-11-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $39,257,708.00
N/A
Revenue This Year
$65.44
N/A
Revenue Next Year
$210.77
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 162.80
N/A
52 Week Low
$4.02
$0.29
52 Week High
$19.71
$27.40

Technical Indicators

Market Signals
Indicator
UAMY
PMN
Relative Strength Index (RSI) 31.90 27.95
Support Level N/A $9.20
Resistance Level $5.70 $15.37
Average True Range (ATR) 0.19 1.00
MACD -0.04 -0.38
Stochastic Oscillator 9.82 4.66

Price Performance

Historical Comparison
UAMY
PMN

About UAMY United States Antimony Corporation

United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has two operating segments: antimony and zeolite. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the Domestic, Canada, and Mexico, of which the vast majority of its revenue comes from the Domestic.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

Share on Social Networks: